GSK1360707

GSK1360707 is an investigational small molecule drug developed by GSK as a potent triple reuptake inhibitor, targeting the reuptake of dopamine, norepinephrine, and serotonin. It acts by inhibiting the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), thereby increasing synaptic concentrations of these neurotransmitters in the brain. Preclinical studies demonstrated that GSK1360707 increases levels of all three monoamines in key brain regions associated with mood regulation and exhibits antidepressant-like effects in animal models. The drug was evaluated for its potential use in treating major depressive disorder (MDD) but has not advanced beyond early clinical trials[3][4][5].

Other names

1013098-04-89DE44WJ46X